Physicians' Academy for Cardiovascular Education

Targeting the PCSK9 pathway: where do novel therapies fit in?

Listen to the podcast
10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD - Dallas, TX, USA

Video navigation menu

  • PCSK9 mAb - mechanism of action 1:36
  • FOURIER and ODYSSEY trials 2:55
  • Guidelines 8:07
  • Inclisiran - mechanism of action 9:41
  • ORION program 11:05
  • What's next in lipid lowering? 13:21


Show transcript

Educational information

This lecture by Ann Marie Navar was part of the EBAC-accredited symposium "A decade of innovation, guidelines, and paradigm shifts in LDL-c management" held during the ESC congress 2022.


Ann Marie Navar, MD, PhD, is an Associate Professor in the Departments of Internal Medicine and Population and Data Sciences and a member of the Division of Cardiology at UT Southwestern Medical Center in Dallas, TX, USA.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by unrestricted educational grants from Daiichi-Sankyo, New Amsterdam Pharma, Novartis, Sanofi & Ultragenyx.

View slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: